GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Cyclically Adjusted PB Ratio

IRLAB Therapeutics AB (OSTO:IRLAB A) Cyclically Adjusted PB Ratio : 0.73 (As of Jun. 26, 2025)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Cyclically Adjusted PB Ratio?

As of today (2025-06-26), IRLAB Therapeutics AB's current share price is kr3.85. IRLAB Therapeutics AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was kr5.29. IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio for today is 0.73.

The historical rank and industry rank for IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio or its related term are showing as below:

OSTO:IRLAB A' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.28   Med: 1.34   Max: 1.39
Current: 1.28

During the past years, IRLAB Therapeutics AB's highest Cyclically Adjusted PB Ratio was 1.39. The lowest was 1.28. And the median was 1.34.

OSTO:IRLAB A's Cyclically Adjusted PB Ratio is ranked better than
53.8% of 684 companies
in the Biotechnology industry
Industry Median: 1.49 vs OSTO:IRLAB A: 1.28

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

IRLAB Therapeutics AB's adjusted book value per share data for the three months ended in Mar. 2025 was kr0.089. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr5.29 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


IRLAB Therapeutics AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Cyclically Adjusted PB Ratio Chart

IRLAB Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IRLAB Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 1.50

Competitive Comparison of IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio falls into.


;
;

IRLAB Therapeutics AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.85/5.29
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRLAB Therapeutics AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, IRLAB Therapeutics AB's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.089/132.8245*132.8245
=0.089

Current CPI (Mar. 2025) = 132.8245.

IRLAB Therapeutics AB Quarterly Data

Book Value per Share CPI Adj_Book
201312 0.969 100.541 1.280
201412 1.960 100.225 2.598
201512 3.567 100.276 4.725
201603 0.000 100.751 0.000
201606 0.000 101.019 0.000
201609 0.000 101.138 0.000
201612 4.027 102.022 5.243
201703 5.596 102.022 7.286
201706 5.298 102.752 6.849
201709 4.717 103.279 6.066
201712 4.352 103.793 5.569
201803 3.907 103.962 4.992
201806 5.991 104.875 7.588
201809 5.607 105.679 7.047
201812 5.155 105.912 6.465
201903 4.725 105.886 5.927
201906 3.986 106.742 4.960
201909 3.463 107.214 4.290
201912 4.145 107.766 5.109
202003 6.152 106.563 7.668
202006 5.608 107.498 6.929
202009 5.033 107.635 6.211
202012 7.173 108.296 8.798
202103 6.335 108.360 7.765
202106 5.821 108.928 7.098
202109 8.179 110.338 9.846
202112 7.720 112.486 9.116
202203 7.139 114.825 8.258
202206 6.632 118.384 7.441
202209 6.247 122.296 6.785
202212 5.607 126.365 5.894
202303 4.459 127.042 4.662
202306 3.593 129.407 3.688
202309 2.853 130.224 2.910
202312 2.232 131.912 2.247
202403 1.480 132.205 1.487
202406 1.344 132.716 1.345
202409 0.733 132.304 0.736
202412 0.629 132.987 0.628
202503 0.089 132.825 0.089

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IRLAB Therapeutics AB  (OSTO:IRLAB A) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


IRLAB Therapeutics AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB Business Description

Traded in Other Exchanges
N/A
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines